Stereotactic Body Radiation Therapy (SBRT) for Stage I Non-Small Cell Lung Cancer (NSCLC): Outcomes by Fractionation, Tumor Stage and Location, and Patient Operability

Autor: Eric Xanthopoulos, Stephen M. Hahn, M. Heskel, John C. Kucharczuk, Taine T. Pechet, Michael N. Corradetti, William P. Levin, Joseph S. Friedberg, Ramesh Rengan, Sunil Singhal, John P. Christodouleas, Charles B. Simone, Keith A. Cengel
Rok vydání: 2014
Předmět:
Zdroj: International Journal of Radiation Oncology*Biology*Physics. 90:S659-S660
ISSN: 0360-3016
DOI: 10.1016/j.ijrobp.2014.05.1947
Popis: 11.7%, with chest wall toxicity constituting 5.8% vs 8.6% and pneumonitis 5.8% vs 3.0%, respectively. For central versus non-central lesions, 5-year actuarial local control, distant metastases-free, disease failure-free, and overall survivals (in %) were 79.0 vs 75.4, 49.5 vs 56.7, 37.2 vs 34.3, and 18.3 vs 20.3, respectively. At analysis, crude rates by lesion of local, lobar and regional nodal failure (in %) were 11.2, 4.1 and 13.5, respectively. There were no statistically significant differences in the failure rates between central and non-central lesions for all parameters. Conclusions: A decade’s experience with Lung SBRT using 50 Gy in 5 fractions reveals excellent local control. Patterns of cancer failure are mainly distant. Co-morbidities drive mortality in this population. This schedule is effective independent of tumor location in the lung, with minimal toxicities that are location-dependent. Author Disclosure: G.M. Videtic: None. C. Reddy: None. N. Woody: None. T. Djemil: None. K. Stephans: None.
Databáze: OpenAIRE